Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Ophthalmol ; : 11206721241254405, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38751133

ABSTRACT

INTRODUCTION AND OBJECTIVES: Lid retraction is one of the most common symptoms of Thyroid-Associated Ophthalmopathy (TAO), which potentially precipitates various complications, such as dry eyes, exposure keratopathy, and cosmetic concerns. Local corticosteroid injections, such as triamcinolone, have been proposed as a choice of treatment for TAO. This approach may be a favorable alternative for patients intolerant to the systemic effects of high-dose methylprednisolone. However, the efficacy of this intervention remains unestablished. Hence, our review aims to evaluate the efficacy of triamcinolone injection in reducing lid retraction. METHODS: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and was conducted in three databases (PubMed, Science Direct, and ProQuest). This review included studies that use local triamcinolone injections for patients with thyroid-associated ophthalmopathy. The outcome of interest in this review is lid retraction parameters. RESULTS: From six studies, a total of 392 patients were included. All studies showed significant improvement in lid retraction in the patient who received triamcinolone (all p < 0.05) as shown by ΔMRD (-0.93 mm in 1 month and -1.38 mm in 3 months), ΔMLD (-1.98 mm at 6 months), and Δpalpebral fissure height (-1.68 in 1 month). The majority of studies showed rapid improvement in lid retraction in the first month of therapy. CONCLUSION: Triamcinolone injection is an effective therapy for lid retraction related to thyroid-associated ophthalmopathy.

2.
Korean J Ophthalmol ; 37(4): 328-339, 2023 08.
Article in English | MEDLINE | ID: mdl-37563973

ABSTRACT

PURPOSE: Nonarteritic anterior ischemic optic neuropathy (NAION) is the second most common form of optic neuropathy. Most patients show no improvement over time. Until now, there is still no definitive therapy for NAION. The available literatures on the possible treatment of NAION are quite diverse and controversial. Neuroprotection strategies have been suggested as one of the potential treatments for NAION. This review aims to critically evaluate the literature on neuroprotective strategy for NAION. METHODS: This report was written in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We performed a systematic literature search in Pubmed, Science Direct, Proquest, and Cochrane databases. Only neuroprotective agents that directly work in protecting neurons were included. The outcome of interest in this review is retinal ganglion cell density and apoptosis for animal studies and retinal nerve fiber layer thickness for human studies. RESULTS: The systematic search identified 591 studies of which 24 met the eligibility criteria, including 21 animal studies and three human studies. Only a few of the studies evaluated the same treatments, showing how diverse neuroprotector treatments are currently being evaluated as NAION treatment. From 21 animal studies, 14 studies showed significantly higher retinal ganglion cell density (1.49- to 2.81-fold) with neuroprotective treatment compared to control group. Two of three human studies in this review had also found a beneficial effect of preserving retinal nerve fiber layer thickness in NAION patients. CONCLUSIONS: This review suggests the potential of neuroprotection as a viable option in the quest for an effective treatment strategy for NAION. Further studies, particularly clinical studies, are necessary to establish its efficacy in NAION patients.


Subject(s)
Optic Disk , Optic Neuropathy, Ischemic , Animals , Humans , Optic Neuropathy, Ischemic/therapy , Neuroprotection , Visual Acuity , Tomography, Optical Coherence
3.
Taiwan J Ophthalmol ; 13(2): 184-190, 2023.
Article in English | MEDLINE | ID: mdl-37484606

ABSTRACT

Papilledema is an optic disc swelling with increased intracranial pressure as the underlying cause. Diagnosis of papilledema is made based on ophthalmoscopy findings. Although important, ophthalmoscopy can be challenging for general physicians and nonophthalmic specialists. Meanwhile, artificial intelligence (AI) has the potential to be a useful tool for the detection of fundus abnormalities, including papilledema. Even more, AI might also be useful in grading papilledema. We aim to review the latest advancement in the diagnosis of papilledema using AI and explore its potential. This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. A systematic literature search was performed on four databases (PubMed, Cochrane, ProQuest, and Google Scholar) using the Keywords "AI" and "papilledema" including their synonyms. The literature search identified 372 articles, of which six met the eligibility criteria. Of the six articles included in this review, three articles assessed the use of AI for detecting papilledema, one article evaluated the use of AI for papilledema grading using Frisèn criteria, and two articles assessed the use of AI for both detection and grading. The models for both papilledema detection and grading had shown good diagnostic value, with high sensitivity (83.1%-99.82%), specificity (82.6%-98.65%), and accuracy (85.89%-99.89%). Even though studies regarding the use of AI in papilledema are still limited, AI has shown promising potential for papilledema detection and grading. Further studies will help provide more evidence to support the use of AI in clinical practice.

4.
Taiwan J Ophthalmol ; 12(3): 334-338, 2022.
Article in English | MEDLINE | ID: mdl-36248079

ABSTRACT

This case report aims to describe the first report of bilateral aseptic cavernous sinus thrombosis (CST) with a recent history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A 50-year-old woman presented with bilateral proptosis, decreased vision, and ophthalmoplegia 16 days following CoronaVac® vaccine. The visual acuity of the left eye was 20/150, while the right eye was no light perception with a hyperemic optic nerve head. She had a history of hyperthyroidism and currently on warfarin consumption. Laboratory results depicted elevated free T4, free T3, international normalized ratio, and low protein S and C. Magnetic resonance imaging showed bilateral CST, and high-dose methylprednisolone along with fondaparinux was given. The symptoms were significantly resolved, with the visual acuity of the left eye being improved to 20/20 but not the right eye. Bilateral CST has not been previously reported following inactivated SARS-CoV-2 vaccination. The underlying systemic conditions should be taken into consideration for the possibility of the inactivated SARS-CoV-2 vaccine-related event.

5.
J Ocul Pharmacol Ther ; 38(8): 584-589, 2022 10.
Article in English | MEDLINE | ID: mdl-36074092

ABSTRACT

Purpose: Ethambutol therapy in certain doses and period can cause bilateral ocular intoxication. There is no definitive therapy that has been found to prevent damage to retina neuronal cells in ethambutol optic neuropathy (EON) cases. Citicoline is thought to have a potential effect to maintain retinal neuron cells. This study aimed to analyze the effect of citicoline on damaged rat ganglion cells in EON. Methods: An experimental study of 15 Wistar rats was divided into 3 groups: the nontreatment group (A), the ethambutol (35 mg/kg/day) group (B), and the ethambutol (35 mg/kg/day) and citicoline (1 g/kg/day) group (C). Groups B and C were given treatment orally for 30 days, then a histopathology examination was performed to analyze retinal ganglion cell (RGC) density, and immunohistochemistry to assess bcl-2 and caspase-3 expression. Results: RGC density of rat with ethambutol intoxication that received citicoline was higher than those who did not get citicoline (P < 0.001). The rat retina ganglion layer without citicoline administration is thicker than the one with citicoline, the increase in thickness is due to the formation of vacuoles in the cytoplasm of ganglion cells. Rat with citicoline obtained higher bcl-2 ganglion expression, and lower caspase-3 expression compared with rat without citicoline. Conclusions: The ganglion cells damage process caused by EON can be suppressed by citicoline administration. It was proven by analyzing RGC density, ganglion layer thickness, and expression level of bcl-2 and caspase-3 on rat model.


Subject(s)
Ethambutol , Optic Nerve Diseases , Rats , Animals , Ethambutol/pharmacology , Retinal Ganglion Cells , Cytidine Diphosphate Choline/pharmacology , Caspase 3/metabolism , Caspase 3/pharmacology , Immunohistochemistry , Rats, Wistar , Optic Nerve Diseases/diagnosis , Proto-Oncogene Proteins c-bcl-2/pharmacology , Retina/metabolism
6.
Korean J Med Educ ; 33(4): 419-430, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34875158

ABSTRACT

Since coronavirus disease 2019 was declared a global pandemic by the World Health Organization, it has become a challenging situation to continue medical education, including in Indonesia. The situation prohibited face-to-face (direct) educational activities in clinical settings, therefore also postponing examinations involving especially procedural skills. Adaptations were urgently needed to maintain the delivery of high-stake examinations to sustain the number of ophthalmology graduates and the continuation of eye health service. Objective structured clinical examination (OSCE) has been one of our widely used method to assess clinical competencies for ophthalmology residents, and is the one method that involves gatherings, close contact of examiners, examinees and patients, therefore the most difficult to adjust. Pandemic challenges brought technical changes in our delivering the OSCE to online, maximizing digital platforms of meetings, while still concerned to guarding the safety of candidates, patients and staffs. OSCE scenarios were also made as timely efficient as possible by changing continuous station models to a cascade one. The purpose of this article is to document our experience in conducting a feasible and reproducible OSCE in this pandemic era filled with limitations.


Subject(s)
COVID-19 , Internship and Residency , Ophthalmology , Clinical Competence , Educational Measurement , Health Services , Humans , Ophthalmology/education , SARS-CoV-2
7.
J Ocul Pharmacol Ther ; 37(9): 534-541, 2021 11.
Article in English | MEDLINE | ID: mdl-34495749

ABSTRACT

Purpose: This study aims to evaluate the effect of citicoline administration in suppressing retinal damage due to methanol intoxication. This study hypothesizes that citicoline will minimize the loss of retinal ganglion cells (RGCs), minimize disruption of photoreceptors, suppress ganglion layer edema, increase expression of bcl-2 as the antiapoptotic protein, and decrease expression of caspase-3 as the proapoptotic protein. Methods: Fifteen Sprague-Dawley rats were divided into 5 groups, including the control group (A); methanol groups, observed on day 3 (B1) and day 7 (B2); and methanol+citicoline groups, observed on day 3 (C1) and day 7 (C2). Rats in groups B and C were placed in an inhalation chamber filled with N2O:O2 during the experiment, then methanol was administered orally. Citicoline, 1 g/kg every 24 h, was orally administered for group C. Enucleation was performed and retinas of rats were prepared for histology and immunohistochemistry examination to evaluate photoreceptor morphology and RGC density, as well as bcl-2 and caspase-3 expression. Results: RGC density of citicoline-treated intoxicated rats was higher than no-citicoline methanol-intoxicated rats on both day 3 (P < 0.001) and day 7 (P < 0.001). The ganglion layer thickness of citicoline-treated intoxicated rats was thinner than no-citicoline intoxicated rats, which means citicoline-treated rats had milder ganglion layer edema. Citicoline-treated rats showed higher bcl-2 and lower caspase-3 expression than no-citicoline rats. No differences were found in photoreceptor findings among groups. Conclusions: This study demonstrated citicoline's potential benefits for management of ocular methanol intoxication. However, more preclinical and clinical trials are needed to obtain a preferred dosage and timing of citicoline administration.


Subject(s)
Cytidine Diphosphate Choline/pharmacology , Methanol/poisoning , Nootropic Agents/pharmacology , Retina/drug effects , Toxic Optic Neuropathy/pathology , Animals , Caspase 3/drug effects , Disease Models, Animal , Male , Photoreceptor Cells/drug effects , Proto-Oncogene Proteins c-bcl-2/drug effects , Rats , Rats, Sprague-Dawley , Retinal Ganglion Cells/drug effects
8.
Acta Med Indones ; 53(2): 221-224, 2021 Apr.
Article in English | MEDLINE | ID: mdl-34251352

ABSTRACT

This is a case of 42nd year-old woman with history of sight loss in her both eyes. She experienced headache and visual field decrease gradually since 2014. After several laboratory and imaging examinations, from her dynamic pituitary magnetic resonance imaging (MRI), it is concluded that she had a giant adenoma of the pituitary gland which compressed to her optic chiasm. From her pituitary laboratory hormone panel, it is revealed that the tumor is a non-functioning pituitary adenoma. From the neuro-ophthalmology (campimetry) examinations, she had papillae atrophy in her both eyes and also bilateral temporal hemianopia.


Subject(s)
Adenoma/radiotherapy , Adenoma/surgery , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Adenoma/pathology , Adult , Craniotomy , Female , Hemianopsia/pathology , Humans , Magnetic Resonance Imaging , Neoplasm Recurrence, Local , Optic Nerve/pathology , Pituitary Neoplasms/pathology
9.
Acta Med Indones ; 51(4): 364-371, 2019 Oct.
Article in English | MEDLINE | ID: mdl-32041923

ABSTRACT

Graves' ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves' disease, based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves' ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.


Subject(s)
Graves Ophthalmopathy/diagnosis , Graves Ophthalmopathy/therapy , Anti-Inflammatory Agents/therapeutic use , Combined Modality Therapy , Decompression, Surgical , Disease Management , Glucocorticoids/therapeutic use , Graves Ophthalmopathy/drug therapy , Graves Ophthalmopathy/radiotherapy , Humans , Immunosuppressive Agents/therapeutic use , Phosphodiesterase Inhibitors/therapeutic use , Radiotherapy Dosage , Radiotherapy, Conformal/methods , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL
...